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Abstract
Background: Traditional concordance metrics have shortcomings based on dataset characteristics (e.g., multiple
attributes rated, missing data); therefore it is necessary to explore supplemental approaches to quantifying
agreement between independent assessments. The purpose of this methodological paper is to apply an Item
Response Theory (IRT) -based framework to an existing dataset that included unidimensional clinician and multiple
attribute patient ratings of symptomatic adverse events (AEs), and explore the utility of this method in patient-
reported outcome (PRO) and health-related quality of life (HRQOL) research.
Methods: Data were derived from a National Cancer Institute-sponsored study examining the validity of a
measurement system (PRO-CTCAE) for patient self-reporting of AEs in cancer patients receiving treatment (N = 940).
AEs included 13 multiple attribute patient-reported symptoms that had corresponding unidimensional clinician AE
grades. A Bayesian IRT Model was fitted to calculate the latent grading thresholds between raters. The posterior
mean values of the model-fitted item responses were calculated to represent model-based AE grades obtained
from patients and clinicians.
Results: Model-based AE grades showed a general pattern of clinician underestimation relative to patient-graded
AEs. However, the magnitude of clinician underestimation was associated with AE severity, such that clinicians’
underestimation was more pronounced for moderate/very severe model-estimated AEs, and less so with mild AEs.
Conclusions: The Bayesian IRT approach reconciles multiple symptom attributes and elaborates on the patterns of
clinician-patient non-concordance beyond that provided by traditional metrics. This IRT-based technique may be
used as a supplemental tool to detect and characterize nuanced differences in patient-, clinician-, and proxy-based
ratings of HRQOL and patient-centered outcomes.
Trial registration: ClinicalTrials.gov NCT01031641. Registered 1 December 2009.
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Background
Levels of concordance, specifically the degree to which
two or more individuals agree when independently rat-
ing something such as the severity of pain, can be calcu-
lated using a number of different statistical metrics (e.g.,
Cohen’s weighted κ, Spearman’s r) [1, 2]. While each of
these statistical tests allow for a single coefficient to
quantify concordance, they do not reflect the degree to
which these levels of agreement may differ based on the
variability of the individual(s) assigning the rating (e.g., a
clinician or patient). Additionally, the characteristics of
the dataset of interest, including the type of response
scale used, the base-rate of responses (i.e., proportion of
positive, negative or zero values in the sample), and the
ratio of raters to items can impact the degree to which
these traditional metrics can be confidently interpreted
as being accurate [3, 4]. In our research comparing pa-
tients’ self-reports with providers’ ratings of symptom se-
verity using an ordinal response scale, we have seen the
inter-rater agreement highly dependent on the preva-
lence of the symptom; a high proportion of 0–0 (i.e.,
None – None) pairs of ratings will cause the statistics to
show an inflated level of agreement when that may not
be the case among the subset of patients who experi-
enced the symptom [5].
A supplemental approach to the calculation of concord-
ance was proposed by Baldwin [6] using a Graded Re-
sponse Model (GRM) to explicitly model the item
response probability. In this example, independent ortho-
pedic surgeons made use of a four-level severity classifica-
tion to review radiographs and rate patient hip fracture
severity. A Bayesian GRM was applied, in which surgeons
were treated like items in GRM so that the item parame-
ters were taken to represent differences between surgeons’
internal decision criteria. Figure 1 illustrates the subtle dif-
ferences between two orthopedic surgeons. The leftmost
plot shows the four tracelines of the probability of surgeon
A’s classifications for the four hip fracture severity levels.
As the underlying severity of a hip fracture increases, the
likelihood of a patient being graded with a higher classifi-
cation (from Type I to Type IV fracture) increases. The
model-predicted severity for patients’ radiographs 11, 6,
and 3 are superimposed, (i.e., for surgeon A, radiograph 11
is expected to be rated minor (Type I), radiograph 6 is
likely to be judged Type III, and radiograph 3 as Type IV).
For surgeon D, however, the three radiographs are ex-
pected to be rated Type I (which agrees with surgeon A),
category II and III, respectively. The tracelines are analo-
gous to the conventional item characteristic curves in IRT
models, and the item difficulty (i.e., threshold) parameters
in the fitted GRM model represented the surgeons’ deci-
sion cutoffs and the item discrimination represented how
sensitive the surgeons’ responses were with respect to
changes in hip fracture severity. Their model-based, GRM
approach differs from conventional methods in that it can
identify subtle but important differences between raters
(e.g., discordance only emerges at higher levels of latent
hip fracture severity).
Inter-rater disagreement arises because raters differ in
their underlying decision thresholds in a GRM model.
Such a model-based approach offers several advantages.
Raters may differ generally (e.g., some surgeons tend to
assign more severe ratings to most cases). Rater discord-
ance may also be contextual (e.g., surgeons may differ in
how they rate specific cases). These subtle differences
are important in eliciting patient-reported outcomes
(PROs) in a clinical encounter, where, for example, a pa-
tient may report a mild pain to a clinician but later en-
dorse ‘moderate’ pain when given an assessment survey.
Our approach is in principle similar to other IRT-based
approaches to inter-rater differences (e.g., many-facet
Rasch model) [7].
We have previously successfully applied this Bayesian
GRM framework in our own research to explore
Fig. 1 Graded Response Model tracelines depicting two orthopedic surgeons’ responses in classifying hip fracture severity. Note: Posterior mean
severity locations of three patients are superimposed. Plot recreated using published data [6]
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differences between patient-, clinician-, and nurse-based
ratings of symptomatic adverse events (AEs) in the clin-
ical trial setting [8]. However, the data used in that study
included a limited number of unidimensional ratings of
AEs, and were from a single, tertiary cancer center with
limited patient diversity with respect to demographics
and disease type.
The present study builds upon our application of the
Bayesian GRM and explores the concordance between
unidimensional clinician ratings of patients’AEs (e.g., nau-
sea, diarrhea, fatigue), and the patients’ self-report of mul-
tiple attributes (e.g., frequency, severity, interference with
daily activities) of those same symptomatic AEs during
cancer treatment. In this context, concordance refers to
the agreement between expected ratings, given the same
underlying level of an underlying symptoms. We also
sought to demonstrate that IRT has potential applicability
in probing concordance in similar datasets that involve
two or more independent raters of an event, particularly
in patient-centered outcomes research where raters may
include patients, caregiver proxies, and clinicians.
Dataset context
In the United States, AEs are monitored as part of all cancer
clinical trials for the purposes of understanding
treatment-related toxicities and ensuring patient safety.
While currently these AEs are documented by clinicians,
there are emerging efforts to directly capture the patient ex-
perience of symptomatic AEs using PROs for those AEs that
represent symptoms [9]. This has led to a number of studies
that have directly compared the concordance between clin-
ician and patient symptomatic AE ratings [10, 11], with the
majority of these studies demonstrating that AE ratings tend
to be discordant [12, 13]. However, the common metrics
used for quantifying concordance in AE grading are prone
to the aforementioned shortcomings that preclude the isola-
tion of potential sources contributing to this discordance
[14–16]. Additionally, in a naturalistic clinic setting, a given
clinician is responsible for the care of any number of pa-
tients. The variability of the ratings adjudicated by a specific
clinician may be more homogeneous than that from inde-
pendent patients receiving care from the same clinician.
This creates a unique analytic challenge when applying the
Bayesian GRM in estimating multiple clinicians’ decision
thresholds as item difficulties in an IRT model, as there
would be missing clinicians’ ratings for patients not seen by
a given clinician. These issues highlight the need for a sup-
plemental methodological approach to understanding
clinician-patient concordance in AE reporting.
Methods
Participants
The study sample for this secondary analysis included 940
patients receiving active treatment for various malignancies
and participating in an NCI-sponsored multi-institutional
study examining the validity of PRO-CTCAE (Clinical
Trials.gov NCT01031641) [17]. English speaking patients
were eligible to participate if they were ≥ 18 years of age,
were undergoing chemotherapy or radiation therapy for
cancer, and were not cognitively impaired. Data were col-
lected between February 2011 and May 2012. The study
was approved by the institutional review boards at the Na-
tional Cancer Institute and all participating sites. All study
participants provided written informed consent.
Measures
Common Terminology Criteria for Adverse Events version
4(CTCAE [18]) – CTCAE consists of a library of over 700
descriptive terms for clinician-based assessment of patient
AEs related to cancer treatment. Each CTCAE term is
assessed using a 5-point verbal descriptor grading scale,
with each grade following a similar grading convention (i.e.,
0 = not present, 1 =mild, 2 =moderate, 3 = severe and/or
requiring medical intervention but not life-threatening, 4 =
life-threatening consequences, and 5 = death).
Patient-Reported Outcomes version of the Common
Terminology Criteria for Adverse Events (PRO-CTCAE
[17, 19–23]) – PRO-CTCAE is an item library com-
prised of 124 items representing various attributes of 78
discrete CTCAE-derived symptom terms.1 Each item
uses a 0–4 rating scale that is attribute dependent (i.e.,
frequency: (0) never, (1) rarely, (2) occasionally, (3) fre-
quently, (4) almost constantly; severity: (0) none, (1)
mild, (2) moderate, (3) severe, (4) very severe; and inter-
ference with daily activities: (0) not at all, (1) a little bit,
(2) somewhat, (3) quite a bit, (4) very much). In the
present dataset, 13 PRO-CTCAE symptoms included at
least two symptom attributes and a corresponding clin-
ician CTCAE grade: anxiety, dyspnea, edema, fatigue,
feelings that nothing could cheer you up, headache, in-
somnia, mucositis, nausea, pain, problems with concen-
tration, sad or unhappy feelings, vomiting. These 13
symptoms were selected to demonstrate the utility of the
Bayesian GRM to characterize the concordance between
a clinician’s single, unidimensional rating of a symptom-
atic toxicity using CTCAE, and the corresponding pa-
tient ratings of multiple attributes for that symptom.
Procedure
Using hand-held computers, patients completed
PRO-CTCAE items evaluating the frequency and severity
(nausea and vomiting), severity and interference (dyspnea,
fatigue, insomnia, mucositis, and problems with concen-
tration), and frequency, severity and interference (anxiety,
edema, headache, pain, feelings that nothing could cheer
you up, and sad or unhappy feelings) of 13 AEs. The data
structure contained conditional branching, such that in
instances where respondents assigned a rating of never (0)
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for the frequency attribute or none for the severity attri-
bute (presented first in the series), the additional attributes
were not presented to them and thus skipped, and for the
purposes of this analysis, were coded as missing [24]. Dur-
ing that same clinic visit, the same 13 AEs were rated by
clinicians using the CTCAE, and documented in the elec-
tronic health record. Although PRO-CTCAE and CTCAE
rating were obtained concurrently, clinicians did not have
access to the PRO-CTCAE responses when assigning their
CTCAE scores.
Statistical analysis
The first step in the Bayesian GRM involved restructuring
the raw data. Unlike Baldwin’s study [6], our raw data con-
tained limitations: 1) each patient was rated by one clin-
ician who provided care; and 2) details on the identity of
the clinicians were unavailable (i.e., which patient or group
of patients were seen by a single clinician at a given study
site). To best approximate such clustering in the data
structure, a composite variable was created, consisting of
all observed unique combinations of institutions and can-
cer types, which yielded each patient being nested within
45 unique institution/cancer combinations. Thus, the
present application of GRM accounted for the decision
thresholds associated with these 45 unique clinician clus-
ters, representing clinic-based aggregate reports, herein-
after referred to as “clinics.” Note that within such clinics,
a given clinician may have rated one or multiple patients,
but no patient was rated by more than one clinician. For
example, clinic 2 might refer to “Site 1, Breast Cancer”,
whereas clinic 15 might refer to “Site 5, Gastrointestinal
Cancer”. Table 1 represents a single symptom example of
the data structure in our analysis, with the columns repre-
senting scale items fitted. For each column, GRM item
discrimination and thresholds were calculated. The pos-
terior mean values of the model-fitted item responses
were calculated to represent model-based AE grades ob-
tained from patients and clinics independently.
As part of any IRT analysis, items are assumed to be
locally independent [25]. In this case local independence
among patient and clinic ratings was assumed to sim-
plify the illustrative examples provided below, with an
additional assumption that there is one single underlying
latent variable representing the multiple attributes for a
given symptom (i.e., frequency, severity, interference
with daily activities). The rating thresholds themselves
are not viewed as latent variables – their existence is in-
ferred because of the observed rating values.
Since all clinics did not assess AEs in all patients, in-
stances where a given clinic did not make a rating were
treated as missing (noted by “N/A”). For example, indi-
vidual clinicians in Clinic 4 may have rated patients
006–012 but no other patients in the dataset. The Bayes-
ian GRM approach updates the parameter estimates
based on available data only, therefore missing data pro-
vides no information with respect to the posterior distri-
butions of the parameters. This permitted the modeling
of decision thresholds across the aggregated clinic clus-
ters in an actual clinical encounter, without the need to
compel a rectangular data structure. In this analysis we
Table 1 Example of data entry structure
PRO-CTCAE CTCAE
Patient ID Frequency Severity Interference Clinic1 Clinic2 Clinic3 Clinic4 Clinic43 Clinic44 Clinic45
001 1 1 1 0 N/A N/A N/A N/A N/A N/A
002 0 – – N/A 1 N/A N/A N/A N/A N/A
003 2 1 2 N/A N/A 1 N/A N/A N/A N/A
004 1 2 0 N/A N/A 1 N/A N/A N/A N/A
005 0 – – N/A N/A 0 N/A N/A N/A N/A
006 1 2 3 N/A N/A N/A 2 N/A N/A N/A
007 2 1 0 N/A N/A N/A 0 N/A N/A N/A
008 1 1 3 N/A N/A N/A 1 N/A N/A N/A
935 2 1 1 N/A N/A N/A N/A 1 N/A N/A
936 0 – – N/A N/A N/A N/A 0 N/A N/A
937 2 2 2 N/A N/A N/A N/A 2 N/A N/A
938 1 1 2 N/A N/A N/A N/A 1 N/A N/A
939 2 1 0 N/A N/A N/A N/A N/A 2 N/A
940 2 2 3 N/A N/A N/A N/A N/A N/A 1
Note: CTCAE indicates Common Terminology Criteria for Adverse Events, PRO-CTCAE indicates Patient-Reported Outcomes version of the Common Terminology for
Adverse Events. Clinic# indicates which of the 45 clinics (grouping clinicians within the same clinic) provided the CTCAE grades. N/A indicates data was not
collected for a given patient in a given clinic. -- indicates PRO-CTCAE data was not captured for the severity and interference attributes for a given adverse event
due to the frequency attribute being assigned a zero (never) rating
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focus on the model-based expected item responses be-
tween patients and clinics. This model-based approach
is advantageous in that it permits the extraction of core
information out of data that contains multiple sources of
variability. Model-based responses represent the most
likely symptom ratings from patients and clinics with
random error variabilities parsed out. The Bayesian
GRM assumes the existence of underlying response
thresholds [26], with threshold cutoffs treated the same
for clinics and patients (e.g., a response of 1 through 4
versus 0, a response of 2 through 4 versus 0 through 1).
These parameter estimates provide the internal stan-
dards that are used by the raters.
The Bayesian GRM item threshold parameters were
given a normal, weakly informative prior with a mean of
1.0 (average slope of 1 in item discrimination) and a
standard deviation of 2.5 [27]. The kappa parameters
were given a normal prior of 0.0 and a standard devi-
ation of 2.5. All analyses were completed using R version
3.4 [28] and JAGS version 4.3.0 [29],2 using shared syn-
tax [30], with 1000 adaptation iterations, 5000 burn-in
iterations, and an additional 8000 iterations (after thin-
ning by 10) kept for the posterior parameter estimates.
Results
Participant characteristics are provided in Table 2. Partici-
pants ranged in age 19–91 years (mean = 58 years; stand-
ard deviation ±12) with varied cancer types. The sample
was predominantly Caucasian (71.8%); 21.6% were Black
or African American; 6% were of Hispanic ethnicity.
PRO-CTCAE responses had a theoretical range of 0–5,
whereas CTCAE ratings had a theoretical range of 0–3.
Tables 3 and 4 display an example of the degree to which
independent CTCAE and PRO-CTCAE ratings for the
symptom of pain vary. Table 3 contains a sample from the
larger dataset to illustrate the observed distribution of
CTCAE pain grades for those patients who endorsed values
of all 1, 2, or 3 for frequency, severity, and interference with
daily activities (n = 83). The first row of the table illustrates
that for the 24 patients in the sample who reported ‘rare-
ly’-occurring, ‘mild’ pain that interfered ‘a little bit’ with
daily activities – a majority of the corresponding ratings of
pain by clinicians were CTCAE grade 1. The second row
shows that ‘occasional’, ‘moderate pain’, that ‘somewhat’ in-
terferes with daily activities was also graded by a majority
of the clinicians as CTCAE grade 1. Thus, intuitively, there
appears to be good concordance between patients’ and cli-
nicians’ ratings in the setting of pain that occurs ‘rarely’, was
‘mild’, and interfered ‘a little bit’ with daily activities (21 of
24 clinicians rated this CTCAE Grade 1). However there
was less agreement among clinicians’ ratings of those pa-
tients who reported ‘occasional’, ‘moderate’ pain, that ‘some-
what’ interferes with daily activities, as seen in the 27
ratings of this experience as CTCAE grade 1, and eight cli-
nicians who rated this as CTCAE grade 2 pain. A similar
discrepancy was observed with ‘frequent’, ‘severe’ pain, that
interferes ‘quite a bit’ with daily activities, where five clini-
cians assigned a CTCAE grade of 3 and 19 assigned a lower
grade (9 grade 1; 10 grade 2).
Table 4 displays the cross-tabulation of clinicians’
CTCAE pain ratings and patients’ PRO-CTCAE pain se-
verity reports. Pain was reported by 525 patients, how-
ever, only 132 pairs of CTCAE and PRO-CTCAE ratings
fall on the main diagonal entries, suggesting discordance
in how patients and clinicians assign their ratings.
Table 5 displays the means, standard deviations of
symptom severity; and the traditional concordance mea-
sures between CTCAE and PRO-CTCAE. PRO-CTCAE
severity was used here for the calculation of concordance
since it was the only attribute captured for every AE in the
Table 2 Patient characteristics (N = 940)
Characteristic No. of Patients (N = 940) %
Age range 19–91
Mean, years (±SD) 58.26
Female 539 57.3
ECOG Performance Status
Median 1.00
Disease
Breast 260 27.7
Lung/Head/Neck 329 35.0
Gastrointestinal 95 10.1
Genitourinary/Gynecologic 172 18.3
Hematological 47 5.0
Other/Unknown 37 3.9
Race
White 675 71.8
Black or African American 203 21.6
Native Hawaiian/Pacific Islander 5 0.5
Asian 42 4.5
Native American/Pacific Islander 2 0.2
Multiple Reported 13 1.4
Note: ECOG indicates Eastern Cooperative Oncology Group
Table 3 Distribution of Raw CTCAE Ratings when PRO-CTCAE
Pain ratings all 1, 2, or 3 (n = 83)
CTCAE Pain Grade
PRO-CTCAE Pain Rating
Frequency Severity Interference 1 2 3
‘rarely’ ‘mild’ ‘a little bit’ 21 3 0
‘occasionally’ ‘moderate’ ‘somewhat’ 27 8 0
‘frequent’ ‘severe’ ‘quite a bit’ 9 10 5
Note: This example represents respondents for which CTCAE and PRO-CTCAE
pain was captured, and where frequency, severity and interference were rated
as all 1, 2, or 3 by patients
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present dataset. The ranges of Cohen’s weighted κ and
Spearman’s r coefficients (i.e., 0.05–0.41 and 0.13–0.58, re-
spectively) indicate a low to moderate association between
CTCAE and PRO-CTCAE severity ratings, while the raw
percentages represent unadjusted levels of agreement be-
tween these two types of ratings.
Graded response model
Overall, the α and κ parameters in a GRM can be con-
ceptualized as the slopes and intercepts, where the
slopes represent how item responses are sensitive to the
underlying latent construct and the intercepts represent
thresholds of consecutive response categories. They offer
a crude but practical representation of patients’ and
clinics’ underlying decision criteria when they assess
pain. Table 6 is a representation of a single AE (i.e.,
pain), and shows a pattern where patients’ α parameter
estimates are generally greater than clinicians’ (as the
latent pain increases, patients tend to report greater pain
at a faster pace than clinics). As for κ thresholds, pa-
tients tend to have lower κ thresholds than clinics in
reporting grade 1 and 2 pain. However, when it comes
to pain levels greater than 2, patient’s thresholds appear
to be comparable to clinics’. The pattern arises from the
observations that, by and large, patients tend to report
grade 1–2 pain while their clinics report grades 0–1
pain. Pain reports above grade 3, however, are uncom-
mon in both patients’ and clinicians’ reports that they
result in roughly comparable GRM estimates.
Figure 2 represents the model-predicted item response
curves for patients, clinics, and the resulting difference be-
tween patient and clinic ratings for the two-attribute
symptoms. The upper leftmost subplot of Fig. 2 displays
the severity and interference ratings for all patients for fa-
tigue, in the same fashion as Baldwin [6] (similar to right
subplot in Fig. 1). The upper center subplot of Fig. 2 illus-
trates the model-estimated clinic CTCAE ratings for fa-
tigue. Each of the 45 clinics have one unique model-based
expected rating profile across θ since each clinic was
treated as an ‘item’ in the model. Clinics were generally
sensitive to different levels of fatigue, as evidenced in the
overall pattern of higher model-based ratings as θ in-
creased. However, there was considerable variability across
clinics, which would be better illustrated by taking the dif-
ference between clinic estimates and patient estimates.
The upper rightmost subplot of Fig. 2 displays the differ-
ence between patients and clinics. Details on the calcula-
tion of the differences are provided here to aid in the
interpretation of the results. We extended the Bayesian
GRM such that patient estimates of severity and
Table 4 Example of cross-tabulation of CTCAE pain grades and
PRO-CTCAE pain severity ratings (n = 525)
CTCAE Pain grade
PRO-CTCAE Pain severity 0 1 2 3 Total
‘none’ 0 2 2 1 0 5
‘mild’ 1 112 85 13 0 210
‘moderate’ 2 56 92 32 3 183
‘severe’ 3 16 33 29 13 91
‘very severe’ 4 4 5 21 6 36
Total 190 217 96 22 525
Note: This sample size represents respondents in whom both CTCAE and PRO-
CTCAE pain ratings were captured
Table 5 Means, standard deviations, and traditional concordance metrics for patient adverse events
Mean (Standard Deviation) Concordance Metric
PRO-CTCAE CTCAE
Adverse Event Frequency Severity Interference Grade Weighted κ Spearman r %
Anxiety 1.18 (1.08) 1.55 (0.79) 1.07 (1.13) 0.48 (0.66) 0.05 0.36* 0.28
Dyspnea ** 0.69 (0.93) 1.32 (1.13) 0.34 (0.60) 0.41* 0.58* 0.64
Edema 0.57 (1.10) 1.68 (0.88) 1.17 (1.28) 0.16 (0.41) 0.07 0.13 0.22
Fatigue ** 1.68 (1.07) 1.80 (1.14) 0.98 (0.77) 0.25* 0.48* 0.37
Feeling Nothing/Cheer Up 0.67 (0.96) 1.43 (0.83) 1.17 (1.05) 0.30 (0.55) 0.09 0.30* 0.25
Headache 0.74 (0.95) 1.46 (0.71) 0.96 (1.00) 0.20 (0.46) 0.05 0.21* 0.19
Insomnia ** 1.13 (1.12) 1.43 (1.12) 0.51 (0.71) 0.29* 0.50* 0.48
Mucositis ** 0.42 (0.84) 1.09 (1.19) 0.16 (0.49) 0.35* 0.47* 0.77
Nausea 0.86 (1.07) 1.55 (0.86) ** 0.33 (0.56) 0.09 0.31* 0.28
Pain 1.35 (1.29) 1.89 (0.95) 1.62 (1.25) 0.61 (0.79) 0.15 0.44* 0.25
Problems w/Concentration ** 0.71 (0.90) 1.24 (0.98) 0.34 (0.54) 0.30* 0.43* 0.58
Sad/Unhappy Feelings 1.14 (0.99) 1.42 (0.76) 0.94 (1.04) 0.30 (0.55) 0.08 0.39* 0.21
Vomiting 0.29 (0.71) 1.51 (0.94) ** 0.10 (0.36) 0.10 0.34* 0.25
Note: Concordance was calculated between PRO-CTCAE severity and CTCAE ratings, ** indicates attribute not assessed, * indicates significant p < 0.01
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interference with daily activities were averaged across all
patients, whereas clinic estimates were calculated separ-
ately for each clinic. In the upper rightmost subplot of Fig.
2, a difference of zero represents perfect concordance,
with positive and negative values representing clinic
underestimation and overestimation of patient-reported
AEs, respectively. The average difference between patient
and clinic estimates was calculated and plotted as the
thick line. The thick line shows that, generally, there is a
reasonable concordance when the thick line is 1 unit
above or below the value of 0 on the y-axis. For fatigue,
this appears to occur between θ values of 1 or less. Clinic
and patients’ expected ratings begin to diverge at theta
values above 1. The divergence reaches a peak of a nearly
2-point difference when the latent fatigue is near θ = 2, 2
standard deviations above the norm.
Additionally, two tick marks are placed along the x-axis
to represent two hypothetical patients; on the left, a pa-
tient (θ = − 0.9) who reported no fatigue (i.e., frequency =
never), and on the right, a patient (θ = 1.0) who reported
frequency as quite a bit and severity as severe. The left tick
mark shows good patient-clinic concordance when fatigue
is absent and the right tick mark shows clinic underesti-
mation by approximately 1 point (on the y-axis) when fa-
tigue is rated as occurring “quite a bit” and having
“severe” severity and “very much” interference with daily
activities. This difference subplot was then repeated for all
two-attribute AEs and displayed within Fig. 2.
Table 6 Bayesian Graded Response Model Estimates for Pain
α parameter κ parameter
Frequency Severity Interference 1–4 vs. 0 2–4 vs. 0–1 3–4 vs. 0–2 4 vs. 0–3
Patient 5.04 5.69 4.33 Frequency −2.58 0.41 3.99 6.98
Severity −6.46 1.21 5.48 9.10
Interference −0.92 1.78 4.25 6.70
Clinic 1 1.88 – – 0.48 2.12 2.69 5.29
Clinic 2 2.31 – – −0.32 2.06 3.84 5.50
Clinic 3 2.09 – – −0.38 2.09 4.25 5.94
Clinic 4 1.16 – – −1.39 1.20 2.34 4.58
Clinic 5 2.38 – – −0.47 2.12 3.32 5.92
Clinic 6 1.54 – – −0.54 1.95 3.85 4.95
Clinic 7 1.31 – – −0.50 2.03 4.10 5.17
Clinic 8 2.02 – – −0.47 0.57 3.95 5.03
Clinic 9 1.94 – – −0.24 2.05 3.31 5.04
Clinic 10 1.14 – – −0.21 1.60 3.30 4.48
Clinic 11 2.23 – – 0.10 1.96 4.83 5.79
Clinic 12 1.92 – – −0.06 1.62 4.13 5.19
Clinic 13 2.44 – – 0.05 1.65 3.72 4.83
Clinic 14 2.14 – – −0.12 2.04 4.06 5.66
Clinic 15 1.11 – – 0.26 2.16 2.94 4.20
Clinic 16 0.53 – – 0.75 2.61 3.70 4.82
Clinic 17 1.27 – – 0.28 1.81 4.03 5.62
Clinic 18 1.62 – – 0.76 2.72 3.92 5.49
Clinic 19 1.93 – – 0.18 3.24 5.16 6.08
Clinic 20 1.99 – – −0.20 2.64 4.52 5.53
Clinic 21 2.88 – – −1.20 1.42 2.33 4.83
Clinic 22 2.52 – – 0.51 2.78 3.90 4.98
Clinic 23 1.95 – – 0.50 2.35 4.76 5.74
Clinic 24 0.66 – – −0.86 0.66 2.98 4.23
Clinic 25 1.12 – – 0.61 1.94 3.50 5.11
Clinic 26 1.24 – – −0.40 1.80 3.34 5.62
Atkinson et al. Journal of Patient-Reported Outcomes            (2018) 2:56 Page 7 of 12
Figure 3 follows a similar format to Fig. 2, with GRM esti-
mates displayed for patients, clinics, and the resulting differ-
ence between patient and clinic ratings for the three-attribute
symptoms. In this case, the upper leftmost subplot of Fig. 3
displays the model-estimated frequency, severity, and inter-
ference PRO-CTCAE ratings for all patients for pain. Similar
to fatigue in Fig. 2, there was an observed overlap of the mul-
tiple attribute ratings as the latent θ -values increased, sug-
gesting that the patients’ ratings of increasing levels of pain
frequency had relatively similar patterns of increased pain se-
verity and interference of pain with daily activities.
The upper rightmost subplot represents the difference
between model-estimates when subtracting clinic esti-
mates from patient estimates, with this subplot repeated
for the remaining three-attribute symptoms. In terms of
pain, there is a reasonable concordance up to 1 standard
deviation above the norm, as shown in the horizontal
thick line near the value of zero. This good concordance
only begins to slowly diverge when latent pain exceeds 1
standard deviation above the norm. The majority of
clinic estimates thus agree reasonably well with patient
estimates. The left tick mark shows that almost all clinic
ratings agree with patient ratings when pain is absent.
However, even for a patient who reports severe pain
(right tick mark), the discordance remains relatively
minor, generally not exceeding a difference of one grade.
Similar good concordance is seen in assessments of
edema and headache. By contrast, concordance is lower
for assessments of anxiety, sad and unhappy feelings,
and the feeling that nothing could cheer you up.
Fig. 2 Graded Response Model Estimates for Patients/Clinicians, and Difference between Patient and Clinicians for Two-Attribute Symptoms. Note:
X-axis represents underlying distribution of AE in the population (θ parameter in the GRM); Y-axis represents the model estimated AE ratings. In
the case of fatigue, θ represents severity and interference with daily activities
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Discussion
The present study demonstrates a step-by-step approach
to successfully applying Bayesian IRT modeling as a
graphical characterization of the concordance between
unidimensional clinician and multiple attribute patient
ratings of symptomatic AEs. Across all AEs, it was ob-
served that CTCAE and PRO-CTCAE ratings were more
concordant at the lower model-estimated thresholds (i.e.,
latent AE value > 1 standard deviation below the norm),
whereas there was increased discordance between clin-
ician and patient reports as the model-estimated grading
thresholds increased. This demonstrates the illustrative
advantages of the IRT approach as a supplement to con-
ventional concordance metrics, in that the IRT approach
can reconcile multiple attribute ratings and better
elucidate nuanced differences between independent rating
sources. Specifically, Figs. 2 and 3 show how concordance
between patients and clinics varies as a function of the AE
level the patient is experiencing.
Conventional concordance metrics such as Cohen’s
weighted ĸ or Spearman’s r provide a single coefficient
that characterizes overall concordance between two rat-
ing sources. In the present dataset, these traditional con-
cordance metrics were low to moderate (Table 5). If this
was the only information presented, one might conclude
that patient ratings deviate considerably from clinic rat-
ings. Additionally, alternative IRT approaches such as
the many-facet model [7] would assume that a single
theta drives all responses; the Bayesian GRM treats them
as separate pieces of information. The Bayesian GRM is
Fig. 3 Graded Response Model Estimates for Patients/Clinicians, and Difference between Patient and Clinicians for Three-Attribute Symptoms.
Note: X-axis represents underlying distribution of AE in the population (θ parameter in the GRM); Y-axis represents the model estimated AE
ratings. In the case of pain, θ represents frequency, severity, and interference with daily activities
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a potential tool that would allow investigators to de-
scriptively explore where discordance may arise. For in-
stance, in the present dataset where there is low
incidence of clinic assignment of elevated AE ratings.
Other methodological advantages of the Bayesian IRT
approach include a pragmatic method to address miss-
ing observations. In the current PRO-CTCAE design,
patients are not prompted to report symptom severity
and/or interference if they first report no symptom fre-
quency. Despite the skip pattern, the Bayesian approach
can still estimate a patient-clinician difference, condi-
tional on a latent model-based symptom distribution.
Envisioned applications of the Bayesian IRT approach
include studies that compare clinician and patient ratings
of PROs more broadly, beyond AEs, including those re-
lated to general health or specific symptoms. Additionally,
these techniques could also be useful when making com-
parisons between independent ratings of HRQOL con-
cepts. An extension of the original framework proposed
by Baldwin [6], where clinical judgments were compared
amongst independent clinicians, might be applied in con-
texts such as the assessment of HRQOL in children and
adolescents, where proxy ratings are also obtained by in-
dependent teachers, clinicians, parents, or other observers
via standardized checklists [31]. Additionally, this Bayesian
IRT technique could be used to analyze archival datasets,
such as the one described in Preen et al. [32], where mul-
tiple data sources were compared to determine the accur-
acy of comorbidity information.
There are a number of potential caveats that should be
considered as analysts apply these methods to other
study contexts where measuring extent of agreement is
salient. While the Bayesian GRM was helpful in elabor-
ating the underlying patterns of discordance between
clinician and patient ratings of AEs, the sources of these
differences are not thoroughly explained through this
method. Additionally, in this context IRT operates under
the assumption that patient and clinic ratings are locally
independent given the model. A formal statistical inves-
tigation of whether such independent ratings are co-
dependent was not made, as it is beyond the scope of
this present study.
Along similar lines, a typical IRT analysis would in-
clude an evaluation of how well the model fits (e.g.,
infit analysis). Unfortunately because of the way the
present data is structured (e.g., patients rate them-
selves), there is insufficient information to complete
such an analysis. Future studies that plan to incorpor-
ate this Bayesian IRT technique should plan to collect
necessary information to evaluate model fit. In
addition, there should be caution with interpretation
of the tracelines, as there may be more error around
the tracelines in the right side of the symptom con-
tinuum in Figs. 2 and 3 due to sparseness of data
(i.e., where respondents are reporting more severe
AEs). However, the patterns observed in the IRT
models are consistent with prior literature that clini-
cians underreport the severity of symptoms compared
to patients [12, 13].
Lastly, clinician-level data was not captured by all sites
during the original study, making it unclear as to which
clinicians assigned ratings to which patients. As such, to
apply the Bayesian GRM framework, a clinic-based ag-
gregate variable consisting of cross-tabulations between
study site and patient disease type was calculated to ap-
proximate clinic ratings of symptoms. Since it is possible
that information about clinician rating variability was
lost during this calculation, future studies may benefit
from explicit coding of the multi-level data structure
which clinicians rated each particular patient or group
of patients. Given these limitations, it should be noted
that the purpose of the present study was not to evaluate
the linkage between CTCAE and PRO-CTCAE ratings
and thus should not be considered as a commentary on
the psychometric properties of PRO-CTCAE, which
have been well-established elsewhere [17]. Future work
that attempts to equate PRO-CTCAE ratings made by
patients with CTCAE ratings assigned by clinicians
should consider including cognitive interview techniques
[33] to qualitatively assess patient perception of life
threatening AEs and/or disease.
Conclusions
We demonstrated that this IRT-based Bayesian GRM
can be a useful descriptive tool for understanding and
visualizing the features of a dataset that contained mul-
tiple attribute ratings from multiple raters (i.e., up to
three ratings from a patient and a unidimensional clin-
ician rating). This methodology can help to provide add-
itional insight beyond that derived from traditional
concordance metrics, and should be considered when
the dataset of interest is amenable to such modeling
techniques. Future studies examining concordance
among multiple raters in the assessment of patient-,
clinician-, and/or proxy-reported outcomes may benefit
from the a priori incorporation of IRT into the analyses
to supplement traditional concordance ratings.
Endnotes
1For the most updated version of the PRO-CTCAE
items and permission to use PRO-CTCAE, investigators
should contact the Outcomes Research Branch at the
National Cancer Institute (http://outcomes.cancer.gov/
tools/pro-ctcae.html).
2R/JAGS syntax for this analysis is available from the
authors upon request.
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